Merck KGaA

News

Merck KGaA is slated to acquire UK-based Silence Therapeutics in a $1.3bn deal that would give it a late-stage drug for polycythemia vera.

News

Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.

News

Merck KGaA is poised to increase the size of its life sciences business with an $11.3 billion deal to acquire rival Bio-techne.

News

Three trials of potentially first-in-class therapies for J&J, UCB/Biogen, and Merck KGaA at EULAR have offered hope of new targeted drugs for lupus.

News

Merck KGaA has started working with Remepy on the development of hybrid drugs that combine medicines with digital therapeutics.

News

Merck has teamed up with Valo Health on a project to apply AI to the discovery of novel drug targets and drugs for Parkinson's.